肉苁蓉苯乙醇苷类成分对BSA诱导的肝纤维化大鼠转化生长因子β1表达的影响

doi:10.3969/j.issn.1004-616x.2015.06.001

癌变·畸变·突变 ›› 2015, Vol. 27 ›› Issue (6): 409-414.doi: 10.3969/j.issn.1004-616x.2015.06.001

• 论著 • 下一篇

肉苁蓉苯乙醇苷类成分对BSA诱导的肝纤维化大鼠转化生长因子β1表达的影响

由淑萍¹, 赵军², 木克热木·吐地买提¹, 马龙¹, 张石蕾¹, 刘涛¹

1. 新疆医科大学公共卫生学院毒理学教研室, 新疆乌鲁木齐 830011;
2. 新疆维吾尔自治区药物研究所, 新疆乌鲁木齐 830004

收稿日期:2015-07-21 修回日期:2015-10-15 出版日期:2015-11-30 发布日期:2015-11-30
通讯作者: 刘涛,E-mail:xjmult@163.com;Tel:18997956799 E-mail:xjmult@163.com
作者简介:由淑萍,E-mail:youshupin@163.com。
基金资助:
国家自然科学基金项目(81260624)

The effects of cistanche phenylethanoid glycosides on TGF-β1 expression of rats with hepatic fibrosis induced by BSA

YOU Shuping¹, ZHAO Jun², MUKARAM Tudimat¹, MA Long¹, ZHANG Shilei¹, LIU Tao¹

1. Department of Toxicology, College of Public Health, Xinjiang Medical University, Urumqi 830011;
2. Xinjiang Uygur Autonomous Region Institute of Materia Medica, Urumqi 830004, Xinjiang, China

Received:2015-07-21 Revised:2015-10-15 Online:2015-11-30 Published:2015-11-30

摘要/Abstract

摘要：

目的:观察肉苁蓉苯乙醇苷类成分(CPhGs)对牛血清白蛋白(BSA)诱导的免疫性肝纤维化大鼠肝组织转化生长因子β1(TGF-β1)表达的影响,探讨其治疗肝纤维化的效果及机制。方法:将75只SD大鼠随机分为6组,即正常对照组,肝纤维化模型组,阳性对照组(复方鳖甲软肝片600 mg/kg),以及CPhGs高(500 mg/kg)、中(250 mg/kg)、低(125 mg/kg)剂量组。CPhGs高、中、低剂量组每组各13只,其余每组各12只。采用皮下及尾静脉注射BSA诱导建立大鼠肝纤维化模型,造模同时灌服相应剂量的受试药物,正常对照组和模型组灌胃给予蒸馏水,其余各组均按设定剂量灌胃给药;给药结束后收集大鼠血清、肝组织,采用全自动生化仪检测大鼠肝功能酶指标,包括血清白蛋白(ALB)、血清总胆红素(TB)、血清直接胆红素(DB)水平;放射免疫法检测血清肝纤维化标志包括血清透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PC Ⅲ)、Ⅳ型胶原(Ⅳ-C)含量;ELISA测定血清TGF-β1水平;Masson染色观察肝脏病理组织学变化;免疫组化法测定肝组织中TGF-β1的表达。结果:与模型组相比,CPhGs各剂量组肝纤维化大鼠血清中ALB含量增加,中、高剂量组TB、DB含量降低,各剂量组大鼠肝纤维化指标含量均明显降低(P<0.05或P<0.01),血清TGF-β1含量降低(P<0.01),Masson染色结果显示CPhGs各剂量组肝纤维化程度减轻,均显著低于模型组(P<0.01),各剂量组肝组织中TGF-β1蛋白的表达也明显受到抑制(P<0.05或P<0.01)。结论:CPhGs对BSA诱导的免疫性肝纤维化大鼠具有较好的保护作用,对TGF-β1表达的抑制作用可能是其作用机制之一。

关键词: 肉苁蓉, 苯乙醇苷类, 肝纤维化, 牛血清白蛋白, 转化生长因子β1

Abstract:

OBJECTIVE: To observe the effects of cistanche phenylethanoid glycosides(CPhGs) on TGF-β1 expression of rats with hepatic fibrosis induced by bovine serum albumin(BSA). METHODS: Seventy-five SD rats were randomly divided into six groups:Normal(distilled water-treated),model(BSA-treated),positive drug(BSA-treated+ compound Biejia Ruangan tablets(BJRG,600 mg/kg),and BSA-treated+CPhGs(125,250,500 mg/kg) groups. BSAtreated+CPhGs(125,250,500 mg/kg) groups consisted of 13 rats in each group,and other various group had 12 rats in each group. Using intravenously injected BSA-induced rat liver fibrosis model,rats were fed with different therapeutic drugs for 12 weeks. After the experiment serum and liver tissues of rats were collected. Measurements of serum enzymes,liver fibrosis markers,serum TGF-β1 concentration,Masson staining to show the histopathological changes and the expression of TGF-β1 were recorded. RESULTS: Compared with model group,except for ALB and the low dose group TB and DB,various dose CPhGs groups(125,250,and 500 mg/kg) could significantly lower liver enzymes in serum(P<0.05),liver fibrosis markers(P<0.05),and TGF-β1 content(P<0.01). Moreover,Masson staining showed BSA-treated+CPhGs(125,250,500 mg/kg) groups could alleviate the degree of liver fibrosis,which was significantly lower than the model group(P<0.01). The expression of TGF-β1 protein in liver tissue of different dose groups were also inhibited significantly(P<0.05 or P<0.01). CONCLUSION: CPhGs demonstrated protective effects on hepatic fibrosis induced by BSA in rats,and one of mechanisms maybe the inhibited expression of TGF-β1 in hepatic fibrosis tissue.

Key words: cistanche, phenylethanoid glycosides, liver fibrosis, bovine serum albumin, transforming growth factor-β1

中图分类号:

R285.5

由淑萍, 赵军, 木克热木·吐地买提, 马龙, 张石蕾, 刘涛. 肉苁蓉苯乙醇苷类成分对BSA诱导的肝纤维化大鼠转化生长因子β1表达的影响[J]. 癌变·畸变·突变, 2015, 27(6): 409-414.

YOU Shuping, ZHAO Jun, MUKARAM Tudimat, MA Long, ZHANG Shilei, LIU Tao. The effects of cistanche phenylethanoid glycosides on TGF-β1 expression of rats with hepatic fibrosis induced by BSA[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(6): 409-414.

参考文献

[1] Cohen-Naftaly M,Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease[J]. Therap Adv Gastroenterol,2011,4(6):391-417.
[2] Puche JE,Saiman Y,Friedman SL. Hepatic stellate cells and liver fibrosis[J]. Compr Physiol,2013,3(4):1473-1492.
[3] Hernandez-Gea V,Friedman SL. Pathogenesis of liver fibrosis[J]. Annu Rev Pathol,2011,6(7):425-456.
[4] Kostadinova R,Montagner A,Gouranton E,et al. GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation[J]. Cell Biol Sci,2012,2(1):34-50.
[5] Sohrabpour AA,Mohamadnejad M,Malekzadeh R. Review article:the reversibility of cirrhosis[J]. Aliment Pharmacol Ther,2012,36(9):824-832.
[6] 李媛,宋媛媛,张洪泉.肉苁蓉的化学成分及药理作用研究进展[J].中国野生植物资源,2010,29(1):7-12.
[7] 宋鹏,屠鹏飞.中药肉苁蓉质量控制及评价的研究进展[J].北方药学,2011,8(2):61-62.
[8] 屠鹏飞,姜勇,郭玉海.肉苁蓉研究及其产业发展[J].中国药学杂志,2011,46(12):882-888.
[9] 陈海燕,郝彩琴,郭鸿雁.肉苁蓉药用资源开发与应用研究进展[J].价值工程,2012,31(3):303-305.
[10] 赵微,潘英妮.肉苁蓉苯乙醇苷类成分药理作用研究进展[J].亚太传统医药,2013,9(5):77-79.
[11] 孙朝晖.中药肉苁蓉的药理活性研究进展[J].赤峰学院学报:自然科学版,2010,26(2):70-71.
[12] Peter JH,Hiroshi H.Anti-hepatotoxic activity of extracts and constituents of buddleja species[J].Planta Med,1989, 55(1):123.
[13] 朱启贵,方步武,竺稽能,等.牛血清白蛋白免疫性肝纤维化动物模型的研究[J].中华病理学杂志,1993,22(2):121.
[14] 程明亮,刘三都.肝纤维化的基础与临床[M].北京:人民卫生出版社,1996:146-147.
[15] 常晋芳.丹参酮ⅡA苦参素治疗肝纤维化临床疗效前后对照研究[J].中外妇儿健康,2011,19(7):32.
[16] 成海,刘平,胡义扬,等.中医药抗肝纤维化临床与基础研究进展[J].世界科学技术——中医药现代化,2007, 9(2):112-119.
[17] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中华肝脏病杂志,2006,14(11):161-163, 866-870.
[18] 木克热木·吐地买提,由淑萍,赵军,等.肉苁蓉苯乙醇苷类成分对BSA致大鼠肝纤维化影响的实验研究[J].新疆医科大学学报,2015,38(5):568-570.
[19] 王燕艳.肝硬化患者血清白蛋白、血清总胆红素与肝纤维化标志物的相关性研究[J].陕西医学杂志,2010,39(7):842-843.
[20] 魏金文,附江宁.血清前白蛋白、胆碱醋酶、胆汁酸联合检测对肝硬化分级临床价值评估[J].陕西医学杂志,2005, 34(12):1520-1522.
[21] 张斌.肝纤维化的发病机理研究进展[J].现代诊断与治疗,2004,15(6):355.
[22] 沈鼎明.肝纤维化的发生机制[J].中华肝脏病杂志,2002, 8(4):241.
[23] Bottinger EP,Miao J,Schiffer M,et al.Transforming growth factor beta signal transduction in the kidney[J]. Kidney Blood Press Res,1998,21(2/3/4):259-261.
[24] Rockey DC. Antifibrotic therapy in chronic liver disease[J]. Clin Gastroenterol Hepatol,2005,3(2):95-107.
[25] Parsons CJ,Bradford BU,Pan CQ,et al.Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats[J]. Hepatology,2004,40(5):1106-1115.

肉苁蓉苯乙醇苷类成分对BSA诱导的肝纤维化大鼠转化生长因子β1表达的影响

The effects of cistanche phenylethanoid glycosides on TGF-β1 expression of rats with hepatic fibrosis induced by BSA

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	张石蕾, 由淑萍, 赵军, 刘涛. 肉苁蓉苯乙醇总苷脂质体对BSA致大鼠肝纤维化的保护作用研究[J]. 癌变·畸变·突变, 2019, 31(6): 428-433.
[2]	张石蕾, 由淑萍, 马晓婷, 马龙, 赵军, 刘涛. 肉苁蓉苯乙醇总苷脂质体对大鼠肝星状细胞增殖、凋亡及细胞周期的影响[J]. 癌变·畸变·突变, 2019, 31(4): 289-294.
[3]	由淑萍, 张石蕾, 赵军, 马龙, 刘涛. 毛蕊花糖苷对血小板衍生生长因子BB处理后大鼠肝星状细胞的影响[J]. 癌变·畸变·突变, 2018, 30(6): 473-478.
[4]	胡琼, 由淑萍, 刘涛, 汪波, 刘昕, 蒋远东. 肉苁蓉苯乙醇总苷抗肝癌作用的实验研究[J]. 癌变·畸变·突变, 2018, 30(3): 194-199.
[5]	由淑萍, 赵军, 马龙, 张石蕾, 刘涛. 肉苁蓉苯乙醇总苷及其单体对肝星状细胞增殖和凋亡的影响[J]. 癌变·畸变·突变, 2017, 29(1): 13-17,22.
[6]	由淑萍, 赵军, 马龙, 张石蕾, 刘涛. 肉苁蓉苯乙醇总苷对大鼠肝星状细胞TGF-β1/Smad信号通路表达的影响[J]. 癌变·畸变·突变, 2016, 28(5): 372-376.
[7]	洪振丰；陈艳华；周建衡；李天骄. 蓍草提取物预防慢性肝损伤、肝纤维化的实验研究[J]. , 2007, 19(1): 16-018.